SslE Elicits Functional Antibodies That Impair In Vitro Mucinase Activity and In Vivo Colonization by Both Intestinal and Extraintestinal Escherichia coli Strains

PLoS Pathogens

Volumn 10, Issue 5, 2014, Pages

  Nesta, Barbara ^a   Valeri, Maria ^a   Spagnuolo, Angela ^a   Rosini, Roberto ^a   Mora, Marirosa ^a   Donato, Paolo ^a   Alteri, Christopher J ^b   Del Vecchio, Mariangela ^a   Buccato, Scilla ^a   Pezzicoli, Alfredo ^a   Bertoldi, Isabella ^a   Buzzigoli, Lapo ^a   Tuscano, Giovanna ^a   Falduto, Maria ^a   Rippa, Valentina ^a   Ashhab, Yaqoub ^c   Bensi, Giuliano ^a   Fontana, Maria Rita ^a   Seib, Kate L ^d   Mobley, Harry L T ^b   Pizza, Mariagrazia ^a   Soriani, Marco ^a   Serino, Laura ^a   more..

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c PALESTINE POLYTECHNIC UNIVERSITY   (Palestine)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; ESCHERICHIA COLI PROTEIN; HYALURONATE LYASE; POLYSACCHARIDE LYASE; SSLE PROTEIN, E COLI; VIRULENCE FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY PRODUCTION; CBA MOUSE; CELL CULTURE; DRUG EFFECTS; ENTEROPATHOGENIC ESCHERICHIA COLI; ENZYME ACTIVATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INTESTINE; METABOLISM; MICROBIOLOGY; MOUSE; OUTBRED STRAIN;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CELLS, CULTURED; ENTEROPATHOGENIC ESCHERICHIA COLI; ENZYME ACTIVATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; INTESTINES; MICE; MICE, INBRED CBA; POLYSACCHARIDE-LYASES; VIRULENCE FACTORS;

EID: 84901688188     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004124     Document Type: Article

References (53)

1. Kaper JB, Nataro JP, Mobley HL, (2004) Pathogenic Escherichia coli. Nat Rev Microbiol 2: 123-140.
2. Hartland EL, Leong JM, (2013) Enteropathogenic and enterohemorrhagic E. coli: ecology, pathogenesis, and evolution. Front Cell Infect Microbiol 3: 15.
3. Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, et al. (2013) Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 26: 822-880.
4. Gibson JS, Cobbold RN, Trott DJ, (2010) Characterization of multidrug-resistant Escherichia coli isolated from extraintestinal clinical infections in animals. J Med Microbiol 59: 592-598.
5. van der Donk C, van de Bovenkamp J, Bamelis H, Driessen C, Feldhoff KH, et al. (2013) Prevalence and spread of multidrug-resistant Escherichia coli including ST131 in different patient populations in the Euroregion Meuse-Rhine. Future Microbiol 8: 1027-1037.
6. van der Donk CF, Schols JM, Driessen CJ, Hagenouw RG, Meulendijks A, et al. (2013) Prevalence and spread of multidrug resistant Escherichia coli isolates among nursing home residents in the southern part of The Netherlands. J Am Med Dir Assoc 14: 199-203.
7. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, et al. (2013) Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 207: 919-928.
8. Papadimitriou M, Voulgari E, Ranellou K, Koemtzidou E, Lebessi E, et al. (2011) Emergence of VIM-1 metallo-beta-lactamase-producing Escherichia coli in a neonatal intensive care unit. Microb Drug Resist 17: 105-108.
9. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P, (2010) Emergence of metallo-beta-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob Agents Chemother 54: 4914-4916.
10. Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, et al. (2010) Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A 107: 9072-9077.
11. Moriel DG, Rosini R, Seib KL, Serino L, Pizza M, et al. (2012) Escherichia coli: great diversity around a common core. MBio 3: 3 may/june 2012; doi:10.1128/mBio.00118-12.
12. Iguchi A, Thomson NR, Ogura Y, Saunders D, Ooka T, et al. (2009) Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69. J Bacteriol 191: 347-354.
13. Yang J, Baldi DL, Tauschek M, Strugnell RA, Robins-Browne RM, (2007) Transcriptional regulation of the yghJ-pppA-yghG-gspCDEFGHIJKLM cluster, encoding the type II secretion pathway in enterotoxigenic Escherichia coli. J Bacteriol 189: 142-150.
14. Baldi DL, Higginson EE, Hocking DM, Praszkier J, Cavaliere R, et al. (2012) The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli. Infect Immun 80: 2042-2052.
15. Hernandes RT, De la Cruz MA, Yamamoto D, Giron JA, Gomes TA, (2013) Dissection of the role of pili and the type 2 and 3 secretion systems in adherence and biofilm formation of an atypical enteropathogenic Escherichia coli strain. Infect Immun 81: 3793-802.
16. Korotkov KV, Sandkvist M, Hol WG, (2012) The type II secretion system: biogenesis, molecular architecture and mechanism. Nat Rev Microbiol 10: 336-351.
17. Strozen TG, Li G, Howard SP, (2012) YghG (GspSbeta) is a novel pilot protein required for localization of the GspSbeta type II secretion system secretin of enterotoxigenic Escherichia coli. Infect Immun 80: 2608-2622.
18. Decanio MS, Landick R, Haft RJ, (2013) The non-pathogenic Escherichia coli strain W secretes SslE via the virulence-associated type II secretion system beta. BMC Microbiol 13: 130.
19. Nakjang S, Ndeh DA, Wipat A, Bolam DN, Hirt RP, (2012) A novel extracellular metallopeptidase domain shared by animal host-associated mutualistic and pathogenic microbes. PLoS One 7: e30287.
20. Wang P, Granados RR, (1997) An intestinal mucin is the target substrate for a baculovirus enhancin. Proc Natl Acad Sci U S A 94: 6977-6982.
21. Liu Z, Miyashiro T, Tsou A, Hsiao A, Goulian M, et al. (2008) Mucosal penetration primes Vibrio cholerae for host colonization by repressing quorum sensing. Proc Natl Acad Sci U S A 105: 9769-9774.
22. Silva AJ, Leitch GJ, Camilli A, Benitez JA, (2006) Contribution of hemagglutinin/protease and motility to the pathogenesis of El Tor biotype cholera. Infect Immun 74: 2072-2079.
23. Sheikh J, Czeczulin JR, Harrington S, Hicks S, Henderson IR, et al. (2002) A novel dispersin protein in enteroaggregative Escherichia coli. J Clin Invest 110: 1329-1337.
24. Hsiao A, Liu Z, Joelsson A, Zhu J, (2006) Vibrio cholerae virulence regulator-coordinated evasion of host immunity. Proc Natl Acad Sci U S A 103: 14542-14547.
25. Colina AR, Aumont F, Deslauriers N, Belhumeur P, de Repentigny L, (1996) Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase. Infect Immun 64: 4514-4519.
26. Zhou JS, Gopal PK, Gill HS, (2001) Potential probiotic lactic acid bacteria Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) do not degrade gastric mucin in vitro. Int J Food Microbiol 63: 81-90.
27. Lane MC, Alteri CJ, Smith SN, Mobley HL, (2007) Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S A 104: 16669-16674.
28. Rhee KJ, Cheng H, Harris A, Morin C, Kaper JB, et al. (2011) Determination of spatial and temporal colonization of enteropathogenic E. coli and enterohemorrhagic E. coli in mice using bioluminescent in vivo imaging. Gut Microbes 2: 34-41.
29. Torres AG, Cieza RJ, Rojas-Lopez M, Blumentritt CA, Souza CS, et al. (2012) In vivo bioluminescence imaging of Escherichia coli O104:H4 and role of aerobactin during colonization of a mouse model of infection. BMC Microbiol 12: 112.
30. Smith SN, Hagan EC, Lane MC, Mobley HL, (2010) Dissemination and systemic colonization of uropathogenic Escherichia coli in a murine model of bacteremia. MBio 1(5):: e00262-10 doi:10.1128/mBio.00262-10.
31. Nicklasson M, Sjoling A, von Mentzer A, Qadri F, Svennerholm AM, (2012) Expression of colonization factor CS5 of enterotoxigenic Escherichia coli (ETEC) is enhanced in vivo and by the bile component Na glycocholate hydrate. PLoS One 7: e35827.
32. Bien J, Sokolova O, Bozko P, (2012) Role of Uropathogenic Escherichia coli Virulence Factors in Development of Urinary Tract Infection and Kidney Damage. Int J Nephrol 2012: 681473.
33. Vigil PD, Stapleton AE, Johnson JR, Hooton TM, Hodges AP, et al. (2011) Presence of putative repeat-in-toxin gene tosA in Escherichia coli predicts successful colonization of the urinary tract. MBio 2: e00066-00011.
34. Pastorello I, Rossi Paccani S, Rosini R, Mattera R, Ferrer Navarro M, et al. (2013) EsiB, a Novel Pathogenic Escherichia coli Secretory Immunoglobulin A-Binding Protein Impairing Neutrophil Activation. MBio 4: 4 july/august 2013; doi:10.1128/mBio.00206-13.
35. Nesta B, Spraggon G, Alteri C, Moriel DG, Rosini R, et al. (2012) FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 3: 2 march/april 2012; doi:10.1128/mBio.00010-12.
36. Schluter J, Foster KR, (2012) The evolution of mutualism in gut microbiota via host epithelial selection. PLoS Biol 10: e1001424.
37. Hooper LV, Macpherson AJ, (2010) Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10: 159-169.
38. Rol N, Favre L, Benyacoub J, Corthesy B, (2012) The role of secretory immunoglobulin A in the natural sensing of commensal bacteria by mouse Peyer's patch dendritic cells. J Biol Chem 287: 40074-40082.
39. Jongeneel CV, Bouvier J, Bairoch A, (1989) A unique signature identifies a family of zinc-dependent metallopeptidases. FEBS Lett 242: 211-214.
40. Lenart A, Dudkiewicz M, Grynberg M, Pawlowski K, (2013) CLCAs- a family of metalloproteases of intriguing phylogenetic distribution and with cases of substituted catalytic sites. PLoS One 8: e62272.
41. Carrington SD, Irwin JA, Liu L, Rudd PM, Matthews E, et al. (2012) Analysing mucin degradation. Methods Mol Biol 842: 191-215.
42. Sheng YH, Hasnain SZ, Png CW, McGuckin MA, Linden SK, (2012) Techniques for assessment of interactions of mucins with microbes and parasites in vitro and in vivo. Methods Mol Biol 842: 297-312.
43. Brumbaugh AR, Mobley HL, (2012) Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines 11: 663-676.
44. Wieser A, Romann E, Magistro G, Hoffmann C, Norenberg D, et al. (2010) A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun 78: 3432-3442.
45. Svennerholm AM, Tobias J, (2008) Vaccines against enterotoxigenic Escherichia coli. Expert Rev Vaccines 7: 795-804.
46. Zhang W, Sack DA, (2012) Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines 11: 677-694.
47. Ahmed T, Bhuiyan TR, Zaman K, Sinclair D, Qadri F, (2013) Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev 7: CD009029.
48. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA, (2008) Mucins in the mucosal barrier to infection. Mucosal Immunol 1: 183-197.
49. Grist M, Chakraborty J, (1994) Identification of a mucin layer in the urinary bladder. Urology 44: 26-33.
50. Achtman M, Mercer A, Kusecek B, Pohl A, Heuzenroeder M, et al. (1983) Six widespread bacterial clones among Escherichia coli K1 isolates. Infect Immun 39: 315-335.
51. Klock HE, Lesley SA, (2009) The Polymerase Incomplete Primer Extension (PIPE) method applied to high-throughput cloning and site-directed mutagenesis. Methods Mol Biol 498: 91-103.
52. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
53. Hagberg L, Engberg I, Freter R, Lam J, Olling S, et al. (1983) Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect Immun 40: 273-283.